Protocol Ledger

NCT03584165 · Phase III · COMPLETED

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

Interventional Phase III clinical trial protocol NCT03584165 sponsored by Biogen in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-04 Enrollment: 277 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03584165
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)277 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03584165
Protocol FieldVerified Registry Value
NCT IdentifierNCT03584165
Consolidated Lead SponsorBiogen
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment277 participants (ACTUAL)
Registered Start Date2018-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI